SCHEMBL22993473

SCHEMBL22993473

Fc1c(Br)ccc2c1CNCC2

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PNMT P11086 9/20 0.54
HTR2A P28223 3/20 0.51
HTR2C P28335 3/20 0.51
HTR2B P41595 3/20 0.51
ADRA2A P08913 1/20 0.49
ADRA2B P18089 1/20 0.49
ADRA2C P18825 1/20 0.49
ASIC3 Q9UHC3 1/20 0.46
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
PRCP P42785 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29407560 1.00 PNMT (0.54) PNMTHTR2AHTR2CHTR2BADRA2A
Hydrochloric Acid SCHEMBL23727152 0.98 PNMT (0.53) PNMTHTR2AHTR2CHTR2BADRA2A
SCHEMBL19642911 0.85 HTR2C (0.47) PNMTHTR2AHTR2CHTR2BADRA2A
SCHEMBL31158860 0.82 HTR2C (0.38) PNMTHTR2AHTR2CHTR2BASIC3
SCHEMBL11737280 0.81 PNMT (0.57) PNMTHTR2AHTR2CHTR2BADRA2A
SCHEMBL11742774 0.81 HTR2C (0.55) PNMTHTR2AHTR2CHTR2BADRA2A
SCHEMBL11737864 0.78 PNMT (0.68) PNMTHTR2AHTR2CHTR2BADRA2A
SCHEMBL30098019 0.78 PNMT (0.54) PNMTHTR2AHTR2CHTR2BADRA2A
SCHEMBL11734649 0.78 PNMT (0.54) PNMTHTR2AHTR2CHTR2BADRA2A
SCHEMBL29168702 0.78 HTR2C (0.51) PNMTHTR2AHTR2CHTR2BADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 US disclosed
CN-114206852-A Plasma kallikrein inhibitors 卡尔维斯塔制药有限公司 2022-03-18 CN disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 US disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 US disclosed
WO-2021028649-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 WO disclosed
WO-2021028645-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250080-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 PNMT 2670/4885HTR2A 3739/4885HTR2C 4421/4885
US-11613527-B2 Enzyme inhibitors SERPINB1, KLKB1, SERPINE1 PNMT 2670/4885HTR2A 3739/4885HTR2C 4421/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 PNMT 2670/4885HTR2A 3739/4885HTR2C 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.